Cargando…

Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant

BACKGROUND: Patients with the lupus anticoagulant (LA) are at an increased risk of thrombotic events, which in turn increase the risk of death. Understanding the determinants of thrombotic risk in patients with LA may pave the way towards targeted thromboprophylaxis. In the Vienna Lupus Anticoagulan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Posch, Florian, Gebhart, Johanna, Rand, Jacob H., Koder, Silvia, Quehenberger, Peter, Pengo, Vittorio, Ay, Cihan, Pabinger, Ingrid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345189/ https://www.ncbi.nlm.nih.gov/pubmed/28279213 http://dx.doi.org/10.1186/s12916-017-0807-7

Ejemplares similares

Lupus anticoagulant test persistence over time and its associations with future thrombotic events
por: Colling, Meaghan E., et al.
Publicado: (2022)

Low extracellular vesicle–associated tissue factor activity in patients with persistent lupus anticoagulant and a history of thrombosis
por: Hell, Lena, et al.
Publicado: (2018)

Altered platelet proteome in lupus anticoagulant (LA)-positive patients—protein disulfide isomerase and NETosis as new players in LA-related thrombosis
por: Hell, Lena, et al.
Publicado: (2020)

Thrombin‐generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause
por: Hofer, Stefanie, et al.
Publicado: (2019)

Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized controlled trials
por: Moik, Florian, et al.
Publicado: (2020)

Fibrinolysis and bleeding of unknown cause
por: Mehic, Dino, et al.
Publicado: (2021)

Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D‐Dimer analysis: A prospective study
por: Posch, Florian, et al.
Publicado: (2020)

P1623: LOW LEVELS OF 25(OH) VITAMIN D IN ADULT PRIMARY ITP PATIENTS
por: Schramm, Theresa, et al.
Publicado: (2023)

Antithrombin Activity and Association with Risk of Thrombosis and Mortality in Patients with Cancer
por: Englisch, Cornelia, et al.
Publicado: (2022)

Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art
por: Thaler, Johannes, et al.
Publicado: (2015)

Neutrophil subpopulations and their activation potential in patients with antiphospholipid syndrome and healthy individuals
por: Mauracher, Lisa-Marie, et al.
Publicado: (2020)

The role of ADAMTS‐13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study
por: Obermeier, Hanna L., et al.
Publicado: (2019)

Health-related quality of life is impaired in bleeding disorders of unknown cause: results from the Vienna Bleeding Biobank
por: Mehic, Dino, et al.
Publicado: (2023)

Natural anticoagulants: A missing link in mild to moderate bleeding tendencies
por: Mehic, Dino, et al.
Publicado: (2021)

Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer
por: Moik, Florian, et al.
Publicado: (2020)

Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2018)

A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability
por: Königsbrügge, Oliver, et al.
Publicado: (2016)

Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study
por: Ay, Cihan, et al.
Publicado: (2022)

Bleeding phenotype in nonsevere hemophilia by International Society on Thrombosis and Haemostasis bleeding assessment tool, bleeding frequency, and the joint status
por: Rejtő, Judit, et al.
Publicado: (2023)

Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis
por: Nopp, Stephan, et al.
Publicado: (2020)

Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
por: Moik, Florian, et al.
Publicado: (2021)

Testing lupus anticoagulants in a real-life scenario - a retrospective cohort study
por: Ratzinger, Franz, et al.
Publicado: (2017)

Fibrinolysis in patients with a mild-to-moderate bleeding tendency of unknown cause
por: Gebhart, Johanna, et al.
Publicado: (2016)

Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry
por: Königsbrügge, Oliver, et al.
Publicado: (2016)

Association of complete blood count parameters, d‐dimer, and soluble P‐selectin with risk of arterial thromboembolism in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2019)

P1625: CLINICAL AND LABORATORY CHARACTERISTICS OF ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA IN EASTERN AUSTRIA
por: Rast, Jasmin, et al.
Publicado: (2023)

ABO blood group type and risk of venous thromboembolism in patients with cancer
por: Englisch, Cornelia, et al.
Publicado: (2022)

Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2019)

How I treat cancer-associated thrombosis
por: Moik, Florian, et al.
Publicado: (2020)

Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non‐severe haemophilia A
por: Rejtő, Judit, et al.
Publicado: (2020)

Thrombomodulin in patients with mild to moderate bleeding tendency
por: Mehic, Dino, et al.
Publicado: (2021)

Anti-Phosphatidylserine/Prothrombin Antibodies at Two Points: Correlation With Lupus Anticoagulant and Thrombotic Risk
por: Egri, Natalia, et al.
Publicado: (2021)

Hemostatic biomarkers associated with postpartum hemorrhage: a systematic review and meta-analysis
por: de Moreuil, Claire, et al.
Publicado: (2023)

Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality
por: Riedl, Julia, et al.
Publicado: (2014)

Alterations of blood coagulation in controlled human malaria infection
por: Riedl, Julia, et al.
Publicado: (2016)

Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study
por: Moik, Florian, et al.
Publicado: (2020)

Lupus anticoagulant is an independent risk factor for non-thrombotic in-hospital mortality in COVID-19 patients
por: Constans, Mireia, et al.
Publicado: (2021)

Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma
por: Mir Seyed Nazari, Pegah, et al.
Publicado: (2020)

Thrombotic Risk after a Major Bleeding During Anticoagulation: A Clinical Case
por: Conti, Serenella, et al.
Publicado: (2017)

Prothrombin Is Responsible for the Lupus Cofactor Phenomenon in a Patient with Lupus Anticoagulant/Hypoprothrombinemia Syndrome
por: Pengo, Vittorio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0pvo9hfbeq9f6s9l4trte1t0vm